AUR-AFSP-TTM1-A-8-0-R-A741-41
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.360
- MITOTIC_SPINDLE+0.240
- TNFA_SIGNALING_VIA_NFKB+0.210
- E2F_TARGETS+0.190
- UV_RESPONSE_DN+0.180
- SPERMATOGENESIS+0.170
- ANDROGEN_RESPONSE+0.160
- TGF_BETA_SIGNALING+0.120
- MYC_TARGETS_V1+0.020
- HEME_METABOLISM+0.010
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.680
- INTERFERON_GAMMA_RESPONSE-0.500
- OXIDATIVE_PHOSPHORYLATION-0.480
- ADIPOGENESIS-0.390
- COAGULATION-0.390
- XENOBIOTIC_METABOLISM-0.370
- FATTY_ACID_METABOLISM-0.350
- MYOGENESIS-0.340
- CHOLESTEROL_HOMEOSTASIS-0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AUR-AFUO-TTP1-A-1-0-R-A741-41 | — | D | 0.841 |
| 2 | e356598b-7611-492a-98ed-ef2ec1b77b7a | — | — | 0.827 |
| 3 | SRR627451 | GTEX | — | 0.808 |
| 4 | SRR627462 | GTEX | — | 0.801 |
| 5 | 69550f7f-5251-4657-863b-bd35d69c82c4 | — | — | 0.799 |
| 6 | ERR2598089 | fetal | fetal | 0.797 |
| 7 | MDT-AP-3325 | Med | Medulloblastoma | 0.794 |
| 8 | b503bcc9-714d-40aa-8709-3b4577ce8007 | — | — | 0.792 |
| 9 | TCGA-21-1082-01A-01R-A96U-41 | — | cohortSQ1 | 0.790 |
| 10 | TCGA-AC-A2QH-01B-04R-A22O-07 | — | D | 0.788 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.240 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.190 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.020 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.010 | Temsirolimus | — uncovered |